Search

Your search keyword '"Jouneau, Stéphane"' showing total 149 results
Start Over Author "Jouneau, Stéphane" Publication Year Range Last 3 years
149 results on '"Jouneau, Stéphane"'

1. SPLF/SMFU/SRLF/SFAR/SFCTCV Guidelines for the management of patients with primary spontaneous pneumothorax

Author

Jouneau, Stéphane, Ricard, Jean-Damien, Seguin-Givelet, Agathe, Bigé, Naïke, Contou, Damien, Desmettre, Thibaut, Hugenschmitt, Delphine, Kepka, Sabrina, Le Gloan, Karinne, Maitre, Bernard, Mangiapan, Gilles, Marchand-Adam, Sylvain, Mariolo, Alessio, Marx, Tania, Messika, Jonathan, Noël-Savina, Elise, Oberlin, Mathieu, Palmier, Ludovic, Perruez, Morgan, Pichereau, Claire, Roche, Nicolas, Garnier, Marc, and Martinez, Mikaël

Published
2023
Full Text
View/download PDF

6. SPLF/SMFU/SRLF/SFAR/SFCTCV Guidelines for the management of patients with primary spontaneous pneumothorax: Endorsed by the French Speaking Society of Respiratory Diseases (SPLF), the French Society of Emergency Medicine (SFMU), the French Intensive Care Society (SRLF), the French Society of Anesthesia & Intensive Care Medicine (SFAR) and the French Society of Thoracic and Cardiovascular Surgery (SFCTCV)

Author

Jouneau, Stéphane, Ricard, Jean-Damien, Seguin-Givelet, Agathe, Bigé, Naïke, Contou, Damien, Desmettre, Thibaut, Hugenschmitt, Delphine, Kepka, Sabrina, Gloan, Karinne Le, Maitre, Bernard, Mangiapan, Gilles, Marchand-Adam, Sylvain, Mariolo, Alessio, Marx, Tania, Messika, Jonathan, Noël-Savina, Elise, Oberlin, Mathieu, Palmier, Ludovic, Perruez, Morgan, Pichereau, Claire, Roche, Nicolas, Garnier, Marc, and Martinez, Mikaël

Published
2023
Full Text
View/download PDF

7. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version

Author

Cottin, Vincent, Bonniaud, Philippe, Cadranel, Jacques, Crestani, Bruno, Jouneau, Stéphane, Marchand-Adam, Sylvain, Nunes, Hilario, Wémeau-Stervinou, Lidwine, Bergot, Emmanuel, Blanchard, Elodie, Borie, Raphaël, Bourdin, Arnaud, Chenivesse, Cécile, Clément, Annick, Gomez, Emmanuel, Gondouin, Anne, Hirschi, Sandrine, Lebargy, François, Marquette, Charles-Hugo, Montani, David, Prévot, Grégoire, Quetant, Sébastien, Reynaud-Gaubert, Martine, Salaun, Mathieu, Sanchez, Olivier, Trumbic, Bruno, Berkani, Karim, Brillet, Pierre-Yves, Campana, Marion, Chalabreysse, Lara, Chatté, Gérard, Debieuvre, Didier, Ferretti, Gilbert, Fourrier, Jean-Michel, Just, Nicolas, Kambouchner, Marianne, Legrand, Bertrand, Le Guillou, Frédéric, Lhuillier, Jean-Pierre, Mehdaoui, Anas, Naccache, Jean-Marc, Paganon, Catherine, Rémy-Jardin, Martine, Si-Mohamed, Salim, and Terrioux, Philippe

Published
2023
Full Text
View/download PDF

11. Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort

Author

Cottin, Vincent, Guéguen, Sonia, Nunes, Hilario, Jouneau, Stéphane, Crestani, Bruno, Bonniaud, Philippe, Wemeau, Lidwine, Israël-Biet, Dominique, Reynaud-Gaubert, Martine, Gondouin, Anne, Cadranel, Jacques, Marchand-Adam, Sylvain, Chevereau, Marie, Dufaure-Garé, Isabelle, Amselem, Serge, and Clément, Annick

Published
2022
Full Text
View/download PDF

12. Tracheobronchopathia osteochondroplastica: clinical, bronchoscopic, and comorbid features in a case series

Author

Dumazet, Antoine, Launois, Claire, Lebargy, Francois, Kessler, Romain, Vallerand, Hervé, Schmitt, Pierre, Hermant, Christophe, Dury, Sandra, Dewolf, Maxime, Dutilh, Julien, Abouda, Maher, Ferreira, Marion, Atallah, Ihab, Lachkar, Samy, Charriot, Jérémy, Jouneau, Stéphane, Uzunhan, Yurdagul, Chouabe, Stéphane, Coiffard, Benjamin, Dutau, Hervé, Hagenburg, Jean, Briault, Amandine, Dormoy, Valérian, Lirsac, Marion, Vergnon, Jean-Michel, Deslee, Gaetan, and Perotin, Jeanne-Marie

Published
2022
Full Text
View/download PDF

13. Chronic use of inhaled corticosteroids in patients admitted for respiratory virus infections: a 6-year prospective multicenter study

Author

Luque-Paz, David, Tattevin, Pierre, Loubet, Paul, Bénézit, François, Thibault, Vincent, Lainé, Fabrice, Vanhems, Philippe, Amour, Selilah, Lina, Bruno, Duval, Xavier, L’Honneur, Anne-Sophie, Fidouh, Nadhira, Vallejo, Christine, Alain, Sophie, Galtier, Florence, Foulongne, Vincent, Lagathu, Gisèle, Lenzi, Nezha, Lesieur, Zineb, Launay, Odile, and Jouneau, Stéphane

Published
2022
Full Text
View/download PDF

15. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Naccache, Jean-Marc, Jouneau, Stéphane, Didier, Morgane, Borie, Raphaël, Cachanado, Marine, Bourdin, Arnaud, Reynaud-Gaubert, Martine, Bonniaud, Philippe, Israël-Biet, Dominique, Prévot, Grégoire, Hirschi, Sandrine, Lebargy, François, Marchand-Adam, Sylvain, Bautin, Nathalie, Traclet, Julie, Gomez, Emmanuel, Leroy, Sylvie, Gagnadoux, Frédéric, Rivière, Frédéric, Bergot, Emmanuel, Gondouin, Anne, Blanchard, Elodie, Parrot, Antoine, Blanc, François-Xavier, Chabrol, Alexandre, Dominique, Stéphane, Gibelin, Aude, Tazi, Abdellatif, Berard, Laurence, Brillet, Pierre Yves, Debray, Marie-Pierre, Rousseau, Alexandra, Kerjouan, Mallorie, Freynet, Olivia, Dombret, Marie-Christine, Gamez, Anne-Sophie, Nieves, Ana, Beltramo, Guillaume, Pastré, Jean, Le Borgne-Krams, Aurélie, Dégot, Tristan, Launois, Claire, Plantier, Laurent, Wémeau-Stervinou, Lidwine, Cadranel, Jacques, Chenivesse, Cécile, Valeyre, Dominique, Crestani, Bruno, Cottin, Vincent, Simon, Tabassome, and Nunes, Hilario

Published
2022
Full Text
View/download PDF

16. Prognostic value and predictors of the alteration of the diffusing capacity of the lungs for carbon monoxide in systemic lupus erythematosus.

Author

Tallec, Erwan Le, Bourg, Corentin, Bouzillé, Guillaume, Belhomme, Nicolas, Pabic, Estelle Le, Guillot, Stéphanie, Droitcourt, Catherine, Perlat, Antoinette, Jouneau, Stéphane, Donal, Erwan, and Lescoat, Alain

Subjects
LUNG physiology, PULMONARY function tests, PULMONARY gas exchange, QUALITATIVE research, PREDICTION models, MICROCIRCULATION, SMOKING, LOGISTIC regression analysis, SYSTEMIC lupus erythematosus, SEVERITY of illness index, RETROSPECTIVE studies, INTERSTITIAL lung diseases, QUANTITATIVE research, MULTIVARIATE analysis, DESCRIPTIVE statistics, CONNECTIVE tissue diseases, ODDS ratio, KAPLAN-Meier estimator, LOG-rank test, CARBON monoxide, MEDICAL records, ACQUISITION of data, STATISTICS, LUNG volume measurements, CONFIDENCE intervals, DATA analysis software, DIFFUSION
Abstract

Objectives SLE is a systemic autoimmune disease characterized by heterogeneous manifestations and severity, with frequent lung involvement. Among pulmonary function tests, the measure of the diffusing capacity of the lungs for carbon monoxide (DLCO) is a noninvasive and sensitive tool assessing pulmonary microcirculation. Asymptomatic and isolated DLCO alteration has frequently been reported in SLE, but its clinical relevance has not been established. Methods This retrospective study focused on 232 SLE patients fulfilling the 2019 EULAR/ACR classification criteria for SLE. Data were collected from the patient's medical record, including demographic, clinical and immunological characteristics, while DLCO was measured when performing pulmonary function tests as part of routine patient follow-up. Results At the end of follow-up, DLCO alteration (<70% of predicted value) was measured at least once in 154 patients (66.4%), and was associated with a history of smoking as well as interstitial lung disease, but was also associated with renal and neurological involvement. History of smoking, detection of anti-nucleosome autoantibodies and clinical lymphadenopathy at diagnosis were independent predictors of DLCO alteration, while early cutaneous involvement with photosensitivity was a protective factor. DLCO alteration, at baseline or any time during follow-up, was predictive of admission in intensive care unit and/or of all-cause death, both mainly due to severe disease flares and premature cardiovascular complications. Conclusion This study suggests a link between DLCO alteration and disease damage, potentially related to SLE vasculopathy, and a prognostic value of DLCO on death or intensive care unit admission in SLE. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Prognostic value and predictors of the alteration of the diffusing capacity of the lungs for carbon monoxide in systemic lupus erythematosus

Author

Le Tallec, Erwan, primary, Bourg, Corentin, additional, Bouzillé, Guillaume, additional, Belhomme, Nicolas, additional, Le Pabic, Estelle, additional, Guillot, Stéphanie, additional, Droitcourt, Catherine, additional, Perlat, Antoinette, additional, Jouneau, Stéphane, additional, Donal, Erwan, additional, and Lescoat, Alain, additional

Published
2023
Full Text
View/download PDF

21. Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort

Author

Mabo, Axelle, primary, Borie, Raphael, additional, Wemeau-Stervinou, Lidwine, additional, Uzunhan, Yurdagül, additional, Gomez, Emmanuel, additional, Prevot, Gregoire, additional, Reynaud-Gaubert, Martine, additional, Traclet, Julie, additional, Bergot, Emmanuel, additional, Cadranel, Jacques, additional, Marchand-Adam, Sylvain, additional, Bergeron, Anne, additional, Blanchard, Elodie, additional, Bondue, Benjamin, additional, Bonniaud, Philippe, additional, Bourdin, Arnaud, additional, Burgel, Pierre Regis, additional, Hirschi, Sandrine, additional, Marquette, Charles Hugo, additional, Quétant, Sébastien, additional, Nunes, Hilario, additional, Chenivesse, Cécile, additional, Crestani, Bruno, additional, Guirriec, Yoann, additional, Monnier, Delphine, additional, Ménard, Cédric, additional, Tattevin, Pierre, additional, Cottin, Vincent, additional, Luque Paz, David, additional, and Jouneau, Stéphane, additional

Published
2023
Full Text
View/download PDF

26. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial

Author

Mankikian, Julie, primary, Caille, Agnès, additional, Reynaud-Gaubert, Martine, additional, Agier, Marie-Sara, additional, Bermudez, Julien, additional, Bonniaud, Philippe, additional, Borie, Raphael, additional, Brillet, Pierre-Yves, additional, Cadranel, Jacques, additional, Court-Fortune, Isabelle, additional, Crestani, Bruno, additional, Debray, Marie-Pierre, additional, Gomez, Emmanuel, additional, Gondouin, Anne, additional, Hirschi-Santelmo, Sandrine, additional, Israel-Biet, Dominique, additional, Jouneau, Stéphane, additional, Juvin, Karine, additional, Leger, Julie, additional, Kerjouan, Mallorie, additional, Marquette, Charles-Hugo, additional, Naccache, Jean-Marc, additional, Nunes, Hilario, additional, Plantier, Laurent, additional, Prevot, Grégoire, additional, Quetant, Sébastien, additional, Traclet, Julie, additional, Valentin, Victor, additional, Uzunhan, Yurdagul, additional, Wémeau-Stervinou, Lidwine, additional, Bejan-Angoulvant, Theodora, additional, Cottin, Vincent, additional, and Marchand-Adam, Sylvain, additional

Published
2023
Full Text
View/download PDF

27. Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort

Author

Mabo, Axelle, Borie, Raphael, Wemeau-Stervinou, Lidwine, Uzunhan, Yurdagu¨l, Gomez, Emmanuel, Prevot, Gregoire, Reynaud-Gaubert, Martine, Traclet, Julie, Bergot, Emmanuel, Cadranel, Jacques, Marchand-Adam, Sylvain, Bergeron, Anne, Blanchard, Elodie, Bondue, Benjamin, Bonniaud, Philippe, Bourdin, Arnaud, Burgel, Pierre Regis, Hirschi, Sandrine, Marquette, Charles Hugo, Quétant, Sébastien, Nunes, Hilario, Chenivesse, Cécile, Crestani, Bruno, Guirriec, Yoann, Monnier, Delphine, Ménard, Cédric, Tattevin, Pierre, Cottin, Vincent, Luque Paz, David, and Jouneau, Stéphane

Abstract

BackgroundAutoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease, predisposing to an increased risk of infection. A complete picture of these infections is lacking.Research questionDescribe the characteristics and clinical outcomes of patients diagnosed with aPAP, and to identify risk factors associated with opportunistic infections.MethodsWe conducted a retrospective cohort including all patients diagnosed with aPAP between 2008 and 2018 in France and Belgium. Data were collected using a standardised questionnaire including demographics, comorbidities, imaging features, outcomes and microbiological data.ResultsWe included 104 patients, 2/3 were men and median age at diagnosis was 45 years. With a median follow-up of 3.4 years (IQR 1.7–6.6 years), 60 patients (58%), developed at least one infection, including 23 (22%) with opportunistic infections. Nocardiaspp was the main pathogen identified (n=10). Thirty-five (34%) patients were hospitalised due to infection. In univariate analysis, male gender was associated with opportunistic infections (p=0.04, OR=3.88; 95% CI (1.02 to 22.06)). Anti-granulocyte macrophage colony-stimulating factor antibody titre at diagnosis was significantly higher among patients who developed nocardiosis (1058 (316–1591) vs 580 (200–1190), p=0.01). Nine patients had died (9%), but only one death was related to infection.InterpretationPatients with aPAP often presented with opportunistic infections, especially nocardiosis, which highlights the importance of systematic search for slow-growing bacteria in bronchoalveolar lavage or whole lung lavage.

Published
2024
Full Text
View/download PDF

28. Prevalence and risk factors of asthma in dairy farmers: Ancillary analysis of AIRBAg

Author

Jouneau, Stéphane, primary, Chapron, Anthony, additional, Ropars, Cécile, additional, Marette, Solenne, additional, Robert, Ange-Marie, additional, Gouyet, Thomas, additional, Belleguic, Chantal, additional, Rochefort-Morel, Cécile, additional, Guillot, Stéphanie, additional, Mailloux, Carole, additional, Desrues, Benoît, additional, Viel, Jean-François, additional, Barakat, Jean, additional, Barel, Anne-Laure, additional, Baron, Henri-Pierre, additional, Bassen, Rachel, additional, Behaghel-Baruteau, Florence, additional, Bernier, Cyril, additional, Beyer, Séverine, additional, Boissel, Romain, additional, Brault, Vanessa, additional, Brinchault, Graziella, additional, Bureau, Dominique, additional, Castel, Odile, additional, Cazuguel, Anne-France, additional, Decelle-Trochet, Catherine, additional, Delaunay, Marcel, additional, Delaunay-Lelièvre, Isabelle, additional, Eveno, Bruno, additional, Fekete, Krisztina, additional, Fourmont, Lisa, additional, Guervin, Amandine, additional, Guy, Tiphaine, additional, Héry, Guillaume, additional, Hardouin, Pauline, additional, Hespel, Anne, additional, Jeffray, Nathalie, additional, Jouneau, Stéphane, additional, Koskas, Yves, additional, de Lauzun, Virginie, additional, Lebossé, Antoine, additional, Lecot, Sandrine, additional, Marquette, David, additional, Martin, Virginie, additional, Merzoug, Ahmed, additional, Morel, Hugues, additional, Morer, Jean, additional, Morisseau, Patrick, additional, Oksenhendler, Aurélie, additional, Orhant, Elisabeth, additional, Peron, Dominique, additional, Piguel-Royer, Mauricette, additional, Pinault, Marie, additional, Pousset, Jean-Paul, additional, Presle, Jean-Claude, additional, Raillard, Patrick, additional, Regnault, Bernard, additional, Séguineau, Antoine, additional, Sevin, Anne, additional, Thépault, Fanny, additional, and Verger, Christian, additional

Published
2022
Full Text
View/download PDF

29. Germline Mutations of Telomere-Related Genes are a Major Risk Factor for Liver Disease: A Multicentric Transversal Study

Author

Sidali, Sabrina, primary, Borie, Raphaël, additional, Sicre de Fontbrune, Flore, additional, El Husseini, Kinan, additional, Rautou, Pierre-Emmanuel, additional, Lainey, Elodie, additional, Goria, Odile, additional, Crestani, Bruno, additional, Cadranel, Jacques, additional, Cottin, Vincent, additional, Bunel, Vincent, additional, Dumortier, Jérôme, additional, Jacquemin, Emmanuel, additional, Reboux, Noémi, additional, Hirschi, Sandrine, additional, Bourdin, Arnaud, additional, Meszaros, Magdalena, additional, Dharancy, Sébastien, additional, Hilaire, Sophie, additional, Mallet, Vincent, additional, Reynaud-Gaubert, Martine, additional, Terriou, Louis, additional, Gottrand, Frédéric, additional, Abou Chahla, Wadih, additional, Kahn, Jean-Emmanuel, additional, Carrier, Paul, additional, Saliba, Faouzi, additional, Rubbia-Brandt, Laura, additional, Aubert, John-David, additional, Elkrief, Laure, additional, de Ledinghen, Victor, additional, Abergel, Armand, additional, Tournilhac, Olivier, additional, Houssel, Pauline, additional, Jouneau, Stéphane, additional, Wemeau, Ludivine, additional, Bergeron, Anne, additional, Leblanc, Thierry, additional, Ollivier-Hourmand, Isabelle, additional, Nguyen-Khac, Eric, additional, Morisse-Pradier, Hélène, additional, Ba, Ibrahima, additional, Boileau, Catherine, additional, Roulot-Thoraval, Françoise, additional, Vilgrain, Valérie, additional, Bureau, Christophe, additional, Nunes, Hilario, additional, Naccache, Jean-Marc, additional, Durand, François, additional, Francoz, Claire, additional, Roulot, Dominique, additional, Valla, Dominique-Charles, additional, Paradis, Valérie, additional, Kannengiesser, Caroline, additional, and Plessier, Aurélie, additional

Published
2023
Full Text
View/download PDF

31. Additional file 1 of Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial

Author

Kreuter, Michael, Bendstrup, Elisabeth, Jouneau, Stéphane, Maher, Toby M., Inoue, Yoshikazu, Miede, Corinna, Lievens, Dirk, and Crestani, Bruno

Abstract

Additional file 1: Table S1. Baseline characteristics in subgroups by body mass index (BMI) in the INBUILD trial. Table S2. Association between change in weight (slope) and risk of outcomes over 52 weeks in the INBUILD trial. Table S3. Baseline characteristics of subgroups of subjects by weight loss ≤5% and >5% over the whole INBUILD trial.

Published
2023
Full Text
View/download PDF

32. Risk of Malnutrition in Patients With Systemic Sclerosis‐AssociatedInterstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo‐ControlledSENSCIS Trial

Author

Volkmann, Elizabeth R., McMahan, Zsuzsanna H., Smith, Vanessa, Jouneau, Stéphane, Miede, Corinna, Alves, Margarida, and Herrick, Ariane L.

Abstract

To assess adverse events (AEs) in relation to baseline body mass index (BMI) and the risk of malnutrition in patients with systemic sclerosis–associated interstitial lung disease (SSc–ILD) treated with nintedanib. Among patients with SSc–ILD randomized to receive nintedanib or placebo in the SENSCIS trial, we assessed AEs in subgroups by baseline BMI ≤20 kg/m2and BMI >20 kg/m2, and the risk of malnutrition using a modified version of the Malnutrition Universal Screening Tool (MUST), over 52 weeks. The AE profile of nintedanib was similar between subgroups with a baseline BMI ≤20 kg/m2(n = 61) and a baseline BMI >20 kg/m2(n = 515). In these subgroups, respectively, AEs led to treatment discontinuation in 16.7% and 15.9% of the nintedanib group and 13.5% and 8.0% of the placebo group, respectively. Based on the modified MUST, the proportions of patients who had a low risk of malnutrition at baseline and at their last assessment were 74.0% in the nintedanib group and 78.1% in the placebo group, while the proportions who were classified as at low risk at baseline but at high risk by their last assessment were 4.5% in the nintedanib group and 1.0% in the placebo group. In the SENSCIS trial, most patients with SSc–ILD remained at low risk of malnutrition over 52 weeks, but the proportion at high risk was higher in patients who received treatment with nintedanib compared to those who received placebo. Management of disease manifestations and AEs that may be associated with weight loss is important to reduce the risk of malnutrition in patients with SSc–ILD.

Published
2023
Full Text
View/download PDF

34. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2021. Version intégrale

Author

Cottin, Vincent, Bonniaud, Philippe, Cadranel, Jacques, Crestani, Bruno, Jouneau, Stéphane, Marchand-Adam, Sylvain, Nunes, Hilario, Wémeau-Stervinou, Lidwine, Bergot, Emmanuel, Blanchard, Elodie, Borie, Raphaël, Bourdin, Arnaud, Chenivesse, Cécile, Clément, Annick, Gomez, Emmanuel, Gondouin, Anne, Hirschi, Sandrine, Lebargy, François, Marquette, Charles-Hugo, Montani, David, Prévot, Grégoire, Quetant, Sébastien, Reynaud-Gaubert, Martine, Salaun, Mathieu, Sanchez, Olivier, Trumbic, Bruno, Berkani, Karim, Brillet, Pierre-Yves, Campana, Marion, Chalabreysse, Lara, Chatté, Gérard, Debieuvre, Didier, Ferretti, Gilbert, Fourrier, Jean-Michel, Just, Nicolas, Kambouchner, Marianne, Legrand, Bertrand, Le Guillou, Frédéric, Lhuillier, Jean-Pierre, Mehdaoui, Anas, Naccache, Jean-Marc, Paganon, Catherine, Rémy-Jardin, Martine, Si-Mohamed, Salim, Terrioux, Philippe, Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre national de référence des maladies pulmonaires rares [Lyon] (CRMPM), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), École des Hautes Études en Santé Publique [EHESP] (EHESP), Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hôpital Avicenne [AP-HP], Institut Coeur Poumon [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Pessac, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Maladies génétiques d'expression pédiatrique (U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Nouvel Hôpital Civil de Strasbourg, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Pasteur [Nice] (CHU), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Hypertension arterielle pulmonaire physiopathologie et innovation thérapeutique, Centre Chirurgical Marie Lannelongue (CCML)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Marseille, Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hypoxie et Poumon : pneumopathologies fibrosantes, modulations ventilatoires et circulatoires (H&P), UFR SMBH-Université Sorbonne Paris Nord, Centre Hospitalier Régional d'Orléans (CHRO), Hospices Civils de Lyon (HCL), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Eure-Seine - Hôpital d'Evreux - Vernon (Evreux), Groupe Hospitalier Paris Saint-Joseph (hpsj), Services de Pneumologie, Exploration Fonctionnelle Respiratoire et Cardiologie (Hôpital Louis Pradel), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Association pour l’amélioration de la prise en charge des maladies pulmonaires rares, Hospices Civils de Lyon, and Université Claude Bernard Lyon 1.

Subjects
Biopsy, Biopsie, [SDV]Life Sciences [q-bio], Fibrose pulmonaire, Pneumopathie interstitielle commune, Interstitial lung disease, Common interstitial lung disease, Pneumopathie interstitielle diffuse, Pulmonary fibrosis
Abstract

National audience; BACKGROUND: Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated. METHODS: Under the auspices of the French-speaking Learned Society of Pulmonology and at the initiative of the coordinating reference center, practical guidelines for treatment of rare pulmonary diseases have been established. They were elaborated by groups of writers, reviewers and coordinators with the help of the OrphaLung network, as well as pulmonologists with varying practice modalities, radiologists, pathologists, a general practitioner, a head nurse, and a patients’ association. The method was developed according to rules entitled "Good clinical practice" in the overall framework of the "Guidelines for clinical practice" of the official French health authority (HAS), taking into account the results of an online vote using a Likert scale. RESULTS: After analysis of the literature, 54 recommendations were formulated, improved, and validated by the working groups. The recommendations covered a wide-ranging aspects of the disease and its treatment: epidemiology, diagnostic modalities, quality criteria and interpretation of chest CT, indication and modalities of lung biopsy, etiologic workup, approach to familial disease entailing indications and modalities of genetic testing, evaluation of possible functional impairments and prognosis, indications for and use of antifibrotic therapy, lung transplantation, symptom management, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis. CONCLUSION: These evidence-based guidelines are aimed at guiding the diagnosis and the management in clinical practice of idiopathic pulmonary fibrosis.; Contexte :Depuis les précédentes recommandations françaises publiées en 2017, les connaissances concernant la fibrose pulmonaire idiopathique ont évolué sur de nombreux aspects.Méthodes :Des recommandations pratiques ont été établies à l’initiative du Centre coordonnateur de référence des maladies pulmonaires rares, sous l’égide de la Société de Pneumologie de Langue Française, par un groupe de coordination, un groupe de rédaction, et un groupe de lecture, impliquant l’ensemble du réseau OrphaLung, des pneumologues de divers modes d’exercice, des radiologues, des pathologistes, un médecin généraliste, un cadre de santé, et une association de patients. La méthode a respecté les règles d’élaboration des « Bonnes pratiques cliniques » selon la méthode des « Recommandations pour la pratique clinique » de la Haute Autorité de Santé, incluant un vote en ligne selon une échelle Likert.Résultats :Après une analyse bibliographique, 54 recommandations ont été formulées, améliorées, puis validées par les groupes de travail, portant sur des aspects multiples de la maladie : épidémiologie, modalités diagnostiques, critères de qualité et interprétation du scanner thoracique, indication et réalisation de la biopsie pulmonaire, bilan étiologique, modalités et indications de l’enquête familiale et de l’analyse génétique, évaluation du retentissement fonctionnel et du pronostic, indication et emploi des médicaments antifibrosants, transplantation pulmonaire, prise en charge des symptômes, comorbidités et complications, traitement de l’insuffisance respiratoire chronique, diagnostic et prise en charge des exacerbations aiguës de fibrose.Conclusion :Ces recommandations fondées sur les preuves sont destinées à guider le diagnostic et la prise en charge pratique de la fibrose pulmonaire idiopathique.

Published
2022

35. Treating Acute Severe Eosinophilic Asthma with IL-5 Inhibitors in ICU

Author

Barbarot, Nicolas, primary, Nourry, Emmanuelle, additional, Massart, Nicolas, additional, Legay, François, additional, Debarre, Matthieu, additional, Fillatre, Pierre, additional, Magalhaes, Eric, additional, Mari, Arnaud, additional, Wallois, Julien, additional, Briens, Eric, additional, and Jouneau, Stéphane, additional

Published
2022
Full Text
View/download PDF

36. COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study

Author

Papiris, Spyros A., primary, Campo, Ilaria, additional, Mariani, Francesca, additional, Kallieri, Maria, additional, Kolilekas, Lykourgos, additional, Papaioannou, Andriana I., additional, Gonca Chousein, Efsun, additional, Cetinkaya, Erdogan, additional, Bonella, Francesco, additional, Borie, Raphael, additional, Kokosi, Maria, additional, Pickworth, Thomas, additional, Molina-Molina, Maria, additional, Gasa, Mercè, additional, Radzikowska, Elżbieta, additional, Fijolek, Justyna, additional, Jouneau, Stéphane, additional, Gomez, Emmanuel, additional, McCarthy, Cormac, additional, Bendstrup, Elisabeth, additional, Piotrowski, Wojciech J., additional, Pabary, Rishi, additional, Hadchouel, Alice, additional, Coolen-Allou, Nathalie, additional, Alfaro, Tiago, additional, Robalo Cordeiro, Carlos, additional, Antonogiannaki, Elvira-Markela, additional, Tomos, Ioannis P., additional, Papakosta, Despoina, additional, Kontakiotis, Theodoros, additional, Panagiotou, Panagiota, additional, Douros, Konstantinos, additional, Schams, Andrea, additional, Lettieri, Sara, additional, Papaevangelou, Vassiliki, additional, Kanaka-Gantenbein, Christina, additional, Karakatsani, Anna, additional, Loukides, Stelios, additional, Costabel, Ulrich, additional, Crestani, Bruno, additional, Morgan, Cliff, additional, Tazawa, Ryushi, additional, Bush, Andrew, additional, Griese, Matthias, additional, and Manali, Effrosyni D., additional

Published
2022
Full Text
View/download PDF

37. Arsenic trioxide inhibits the functions of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis

Author

Joannes, Audrey, primary, Morzadec, Claudie, additional, Duclos, Maëla, additional, Gutierrez, Francisco Llamas, additional, Chiforeanu, Dan Cristian, additional, Le Naoures, Cécile, additional, De Latour, Bertrand, additional, Rouzé, Simon, additional, Wollin, Lutz, additional, Jouneau, Stéphane, additional, and Vernhet, Laurent, additional

Published
2022
Full Text
View/download PDF

39. Determinants of survival after lung transplantation in telomerase-related gene mutation carriers: A retrospective cohort

Author

Phillips-Houlbracq, Mathilde, primary, Mal, Hervé, additional, Cottin, Vincent, additional, Gauvain, Clément, additional, Beier, Fabian, additional, Sicre de Fontbrune, Flore, additional, Sidali, Sabrina, additional, Mornex, Jean François, additional, Hirschi, Sandrine, additional, Roux, Antoine, additional, Weisenburger, Gaelle, additional, Roussel, Arnaud, additional, Wémeau-Stervinou, Lidwine, additional, Le Pavec, Jérôme, additional, Pison, Christophe, additional, Marchand Adam, Sylvain, additional, Froidure, Antoine, additional, Lazor, Romain, additional, Naccache, Jean-Marc, additional, Jouneau, Stéphane, additional, Nunes, Hilario, additional, Reynaud-Gaubert, Martine, additional, Le Borgne, Aurélie, additional, Boutboul, David, additional, Ba, Ibrahima, additional, Boileau, Catherine, additional, Crestani, Bruno, additional, Kannengiesser, Caroline, additional, and Borie, Raphaël, additional

Published
2022
Full Text
View/download PDF

40. To be malnourished or not to be malnourished: that is the question!

Author

Ronan Thibault, Mallorie Kerjouan, Jouneau Stéphane, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], Pulmonary and Respiratory Medicine, 03 medical and health sciences, Pediatrics, medicine.medical_specialty, 0302 clinical medicine, 030228 respiratory system, business.industry, [SDV]Life Sciences [q-bio], Medicine, 030212 general & internal medicine, business, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2022

47. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Author

Ilié, Marius, Mazières, Julien, Chamorey, Emmanuel, Heeke, Simon, Benzaquen, Jonathan, Thamphya, Brice, Boutros, Jacques, Tiotiu, Angélica, Fayada, Julien, Cadranel, Jacques, Poudenx, Michel, Moro-Sibilot, Denis, Barlesi, Fabrice, Thariat, Juliette, Clément-Duchêne, Christelle, Tomasini, Pascale, Hofman, Véronique, Marquette, Charles-Hugo, Hofman, Paul, Israel-Biet, Dominique, Pison, Christophe, Lantuejoul, Sylvie, Stephanov, Olivier, Juliette, Meyzenc, Mendozat, Christophe, Zaidi, Manel, Coulouvrat, Sandra, Col, Edwige, Chanez, Pascal, Greillier, Laurent, Mascaux, Céline, Jourdan, Sandrine, Roger, Aurélie, Biemar, Julie, Randriamampionona, Rondro, Chabot, François, Vignaud, Jean-Michel, Lacomme, Stéphanie, Lomazzi, Sandra, Laurent, Carine, Bulsei, Xavier, Bischoff, Laura, Rakotonirina, Raymond, Layouni, Mehdi, Deslee, Gaëtan, Mal, Hervé, Kessler, Romain, Vergnon, Jean-Michel, Pelissier, Isabelle, Cuvelier, Antoine, Bourdin, Arnaud, Jounieaux, Vincent, Roche, Nicolas, Jouneau, Stéphane, Bonniaud, Philippe, Scherpereel, Arnaud, Mornex, Jean François, Steenhouwer, François, Leroy, Sylvie, Marquette, Charles Hugo, Mazzette, Andrea, Padovani, Bernard, Long-Mira, Elodie, Lassalle, Sandra, Pradelli, Johanna, Martinez, Estelle, Habault, Marine, Bonnard, Mélanie, Moutarde, Julie, Yatimi, Rachida, Labsi, Hakima, Gazoppi, Loïc, Lpce, Tumorothèque, Griffonnet, Jennifer, Fontaine, Maureen, Guillemart, Ariane, Butori, Catherine, Selva, Eric, Otto, Josiane, Hebert, Christophe, Botchiellini, Delphine, Boudouf, Soukaina, Menier, Margaux, Occeli, Estelle, Bellentani, Sophie, Pion, Carine, Fournier, Elodie, Gervais, Radj, Hamond, Karim, Marchand-Adam, Sylvain, Plantier, Laurent, Fajolle, Gaelle, Rayez, Mélanie, Fallet, Vincent, Wislez, Marie, Antoine, Martine, Cote, Jean-François, Chaabane, Nouha, Ruppert, Anne Marie, Bertrand, Eliane, Rodenas, Anita, Pontdeme, Gwenaëlle, Mathiot, Nathalie, Ribert, Tamazouzt, Guibert, Nicolas, Rouviere, Damien, Bousquet, Emilie, Bigay-Game, Laurence, Hermant, Christophe, Plat, Gavin, Rouquette, Isabelle, Evrard, Solène, Gouin, Sandrine, Clermont, Estelle Taranchon, Dormoy, Inge, Coulomb, Christelle, Pradine, Anne, Lambert, Véronique, Laborde, Lilian, Castelnau, Olivier, University of Manchester [Manchester], Hôpital du Sacré-Coeur de Montréal, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Yonsei University College of Medicine [Séoul, Corée du Sud], August Pi i Sunyer Biomedical Research Institute - IDIBAPS [Barcelona, Spain], Hospital de la Santa Creu i Sant Pau, University Hospitals Leuven [Leuven], National and Kapodistrian University of Athens (NKUA), Odense University Hospital (OUH), Oregon Health and Science University [Portland] (OHSU), Kyushu University, Hacettepe University = Hacettepe Üniversitesi, University of Copenhagen = Københavns Universitet (UCPH), University of Groningen [Groningen], Abbvie Inc. [North Chicago], Asklepios Klinikum Uckermark GmbH, Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique (COMPO), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche en Cancérologie de Marseille (CRCM), and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, medicine.medical_treatment, CELL LUNG-CANCER, Population, Peripheral edema, Phases of clinical research, [SDV.CAN]Life Sciences [q-bio]/Cancer, Delta-like protein 3, Rovalpituzumab tesirine, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, DRUG, education, ComputingMilieux_MISCELLANEOUS, Chemotherapy, education.field_of_study, Small cell lung cancer, business.industry, Hazard ratio, Confidence interval, 030104 developmental biology, 030220 oncology & carcinogenesis, Topotecan, medicine.symptom, business, medicine.drug
Abstract

INTRODUCTION: DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. The efficacy and safety of Rova-T compared with topotecan as second-line therapy in patients with SCLC expressing high levels of DLL3 (DLL3-high) was evaluated. METHODS: The TAHOE study was an open-label, two-to-one randomized, phase 3 study comparing Rova-T with topotecan as second-line therapy in DLL3-high advanced or metastatic SCLC. Rova-T (0.3 mg/kg) was administered intravenously on day 1 of a 42-day cycle for two cycles, with two additional cycles available to patients who met protocol-defined criteria for continued dosing. Topotecan (1.5 mg/m2) was administered intravenously on days 1 to 5 of a 21-day cycle. The primary end point was overall survival (OS). RESULTS: Patients randomized to Rova-T (n = 296) and topotecan (n = 148) were included in the efficacy analyses. The median age was 64 years, and 77% had the extensive disease at initial diagnosis. The median OS (95% confidence interval) was 6.3 months (5.6-7.3) in the Rova-T arm and 8.6 months (7.7-10.1) in the topotecan arm (hazard ratio, 1.46 [95% confidence interval: 1.17-1.82]). An independent data monitoring committee recommended that enrollment be discontinued because of the shorter OS observed with Rova-T compared with topotecan. Safety profiles for both drugs were consistent with previous reports. CONCLUSIONS: Compared with topotecan, which is the current standard second-line chemotherapy, Rova-T exhibited an inferior OS and higher rates of serosal effusions, photosensitivity reaction, and peripheral edema in patients with SCLC. A considerable unmet therapeutic need remains in this population. ispartof: JOURNAL OF THORACIC ONCOLOGY vol:16 issue:9 pages:1547-1558 ispartof: location:United States status: published

Published
2021

49. Intrapleural use of urokinase and DNase in pleural infections managed with repeated thoracentesis: A comparative cohort study

Author

Luque Paz, David, primary, Bayeh, Betsega, additional, Chauvin, Pierre, additional, Poizeau, Florence, additional, Lederlin, Mathieu, additional, Kerjouan, Mallorie, additional, Lefevre, Charles, additional, de Latour, Bertrand, additional, Letheulle, Julien, additional, Tattevin, Pierre, additional, and Jouneau, Stéphane, additional

Published
2021
Full Text
View/download PDF

50. Idiopathic chronic obliterative bronchiolitis: a multicentric retrospective cohort

Author

Nasser, Mouhamad, primary, Uzunhan, Yurdagül, additional, Hirschi, Sandrine, additional, Jouneau, Stéphane, additional, Lebargy, François, additional, Justet, Aurélien, additional, Taillé, Camille, additional, Wemeau, Lidwine, additional, Valentin, Victor, additional, Borie, Raphael, additional, Godbert, Benoit, additional, Gagnadoux, Frédéric, additional, Guilleminault, Laurent, additional, Nunes, Hilario, additional, Marchand-Adam, Sylvain, additional, Cottin, Vincent, additional, and Nasser, Mouhamad, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results